Unique ID issued by UMIN | UMIN000048321 |
---|---|
Receipt number | R000055072 |
Scientific Title | Randomized controlled trial comparing zinc-BCAA combination therapy with BCAA monotherapy in liver cirrhosis patients with hypoalbuminemia |
Date of disclosure of the study information | 2022/07/11 |
Last modified on | 2022/07/08 15:53:39 |
Randomized controlled trial comparing zinc-BCAA combination therapy with BCAA monotherapy in liver cirrhosis patients with hypoalbuminemia
Randomized controlled trial comparing zinc-BCAA combination therapy with BCAA monotherapy in liver cirrhosis patients with hypoalbuminemia
Randomized controlled trial comparing zinc-BCAA combination therapy with BCAA monotherapy in liver cirrhosis patients with hypoalbuminemia
Randomized controlled trial comparing zinc-BCAA combination therapy with BCAA monotherapy in liver cirrhosis patients with hypoalbuminemia
Japan |
Liver cirrhosis with hypoalbuminemia
Hepato-biliary-pancreatic medicine |
Others
NO
To evaluate the synergistic therapeutic effect of zinc and BCAA on hypoalbuminemia
Efficacy
Changes of serum albumin
1)Achievement rate of serum albumin>3.5g/dL, value of serum albumin
2)Changes of child pugh score, ALBI score
3)Changes of Skeletal muscle index(BIA), grip strength, SARC-F
4)Cumulative incidence rate of HCC
5)Cumulative incidence rate of acute decompensation and ACLF
6)Overall survival
7)Achievement rate of serum zinc>80mcg/dl value, changes of serum zinc
8)Changes of NH3, BTR
9)Changes of liver fibrosis marker(type4 collagen 7s, autotaxine and M2BPGi) and scoring system(FIB4 index, APRI)
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Zinc + BCAA(12g/day). Starting dose of zinc is 50mg/day for <60kg, 75mg/day for 60kg-80kg, 100mg/day for >80kg.
For cases with the serum zinc level is less than 80 mcg/dl at 4 and 8 weeks of administration, the amount of zinc is increased by 25mg/day. Total administration period is 12 weeks.
BCAA(12g/day).
Total administration period is 12 weeks.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Patients with hypozincemia and hypoalbuminemia due to liver cirrhosis, specifically patients who meet all the following conditions
1) Hypozincemia (<70mcg/dl)
2) hypoalbuminemia (<3.5g/dL)
1)Beyond Child-Pugh score 8.
2)Severe hypoalbuminemia (Serum albumin less than 2.8g/dL)
3)Past history of hepatic encephalopathy
4)Doubtful case of Wilson disease
5)Symptomatic hypozincemia
6)Severe renal dysfunction (serum creatinine more than 2.0 mg/dl)
7)Malabsorption due to digestive diseases
8)Poor oral intake due to alcohol use disorder and anorexia nervosa
9)Severe dementia
64
1st name | Nobuhiro |
Middle name | |
Last name | Nkamoato |
Keio University, School of Medicine
Division of Gastroenterology and Hepatology
1608582
35 Shinanomachi Shinjuku-ku, Tokyo
+81-3-3353-1211
nobuhiro@z2.keio.jp
1st name | Ryosuke |
Middle name | |
Last name | Kasuga |
Keio University, School of Medicine
Division of Gastroenterology and Hepatology
1608582
35 Shinanomachi Shinjuku-ku, Tokyo
+81-3-3353-1211
rk-keio2020@keio.jp
Keio University, School of Medicine
Keio University, School of Medicine
Other
Keio University, School of Medicine
35 Shinanomachi Shinjuku-ku, Tokyo
+81-3-3353-1211
med-rinri-jimu@adst.keio.ac.jp
NO
2022 | Year | 07 | Month | 11 | Day |
Unpublished
Preinitiation
2022 | Year | 06 | Month | 14 | Day |
2022 | Year | 06 | Month | 14 | Day |
2022 | Year | 07 | Month | 11 | Day |
2027 | Year | 03 | Month | 31 | Day |
2022 | Year | 07 | Month | 08 | Day |
2022 | Year | 07 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055072